4D Molecular Therapeutics(FDMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FDMT 4D Molecular Therapeutics

Post-Mkt 12-22 16:34:54 EST

8.71

+0.03

+0.35%

盘后8.71

+0.000.00%

16:20 EST

High8.91	Low8.61	Vol832.50K
Open8.75	D1 Closing8.68	Amplitude3.40%
Mkt Cap497.65M	Tradable Cap356.00M	Total Shares57.14M
T/O7.27M	T/O Rate2.04%	Tradable Shares40.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FDMT","market":"US","secType":"STK","nameCN":"4D Molecular Therapeutics","latestPrice":8.71,"timestamp":1766437200000,"preClose":8.68,"halted":0,"volume":832503,"hourTrading":{"tag":"盘后","latestPrice":8.71,"preClose":8.71,"latestTime":"16:20 EST","volume":9942,"amount":86594.82,"timestamp":1766438400415},"delay":0,"floatShares":40873000,"shares":57135100,"eps":-3.744606,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"12-22 16:34:54 EST","open":8.75,"high":8.905,"low":8.61,"amount":7266224.24175,"amplitude":0.033986,"askPrice":8.85,"askSize":600,"bidPrice":8.6,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.744606,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":8.68,"preHourTrading":{"tag":"盘前","latestPrice":8.74,"preClose":8.68,"latestTime":"09:29 EST","volume":2159,"amount":18859.685419999998,"timestamp":1766413799999},"postHourTrading":{"tag":"盘后","latestPrice":8.71,"preClose":8.71,"latestTime":"16:20 EST","volume":9942,"amount":86594.82,"timestamp":1766438400415},"volumeRatio":0.354488,"impliedVol":2.2428,"impliedVolPercentile":0.856},"requestUrl":"/m/hq/s/FDMT","defaultTab":"news","newsList":[{"id":"2592819727","title":"4D Molecular Therapeutics Inc. Files Initial Beneficial Ownership Statement for Officer Christopher Paul Simms","url":"https://stock-news.laohu8.com/highlight/detail?id=2592819727","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592819727?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:12","pubTimestamp":1766178778,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Christopher Paul Simms as the beneficial owner, serving in the role of officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL3DpMt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"4D Molecular Therapeutics Inc. Files Initial Beneficial Ownership Statement for Officer Christopher Paul Simms","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2592972411","title":"Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972411","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592972411?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:11","pubTimestamp":1766178673,"startTime":"0","endTime":"0","summary":"Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL7N9JYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2592905608","title":"4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2592905608","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592905608?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:42","pubTimestamp":1766061720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FDMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 07:42 ET (12:42 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT"],"gpt_icon":0},{"id":"2592999283","title":"4D Molecular Therapeutics Reports Positive Interim Phase 1 Results for 4D-710 in Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592999283","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592999283?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972829,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc. announced positive interim clinical data from its Phase 1 AEROW clinical trial evaluating 4D-710 for the treatment of cystic fibrosis  lung disease. The results showed that the selected Phase 2 dose of 4D-710 was well tolerated, with no severe adverse events related to the drug, and achieved physiologically relevant levels of CFTR expression. Clinically meaningful activity was observed in multiple endpoints, including lung function and quality of life measures, with follow-up through one year. The data were presented in a company webcast on December 17, 2025. Enrollment for the Phase 2 Dose-Expansion cohort is expected to be completed in the first half of 2026, with a program update anticipated in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9rvlDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","BK4112","BK4139","FDMT","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2592994014","title":"4Dmt Announces Positive Interim Clinical Data From 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994014?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA8DLY5V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2591073689","title":"4D Molecular Therapeutics Grants 13,800 RSUs to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2591073689","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591073689?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:05","pubTimestamp":1765573506,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc. has granted 13,800 Restricted Stock Units  to three new non-executive employees as part of its 2025 Employment Inducement Award Plan. The RSUs were approved by the company's board of directors and are intended for newly hired team members.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6FygSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","SG9999014013.SGD","SG9999014039.USD","BK4588","FDMT","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590549789","title":"4D Molecular Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Kristian Humer, Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549789","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549789?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:14","pubTimestamp":1765487655,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Kristian Humer as the beneficial owner in his capacity as Chief Financial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3l4SnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"4D Molecular Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Kristian Humer, Chief Financial Officer","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2589035338","title":"4D Molecular Therapeutics to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2589035338","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589035338?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198830,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 a.m. PT. Members of the company's management team will also be available for one-on-one meetings during the event. An archived webcast of the presentation will be accessible on the 4DMT website for up to one year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbyHbgG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","FDMT","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2584684906","title":"Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584684906","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584684906?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:54","pubTimestamp":1763607283,"startTime":"0","endTime":"0","summary":"Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL6RwYTx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT","BK4139"],"gpt_icon":0},{"id":"2584692673","title":"4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2584692673","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584692673?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571139,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - 4D Molecular Therapeutics Inc ::*4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET AMD SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD3lx8jM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2584678145","title":"Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584678145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584678145?lang=en_us&edition=fundamental","pubTime":"2025-11-18 01:01","pubTimestamp":1763398882,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GeoVax Labs (GOVX – Research Report) and 4D Molecula...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-geovax-labs-govx-and-4d-molecular-therapeutics-fdmt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-geovax-labs-govx-and-4d-molecular-therapeutics-fdmt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","LU0029874061.USD","LABU","XBI","GOVX","BK4581","BK4585","BK4583","BK4588","BK4139","HCSG","FDMT","BK4137"],"gpt_icon":0},{"id":"1151622872","title":"Stock Track | 4D Molecular Therapeutics Soars 5.19% on Appointment of New CFO Kristian Humer","url":"https://stock-news.laohu8.com/highlight/detail?id=1151622872","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151622872?lang=en_us&edition=fundamental","pubTime":"2025-11-17 23:50","pubTimestamp":1763394659,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics (FDMT) stock is soaring 5.19% in Monday's trading session following the announcement of Kristian Humer as the company's new Chief Financial Officer. The appointment comes at...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["FDMT"],"gpt_icon":0},{"id":"2584628639","title":"4D Molecular Therapeutics Names Kristian Humer as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584628639","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584628639?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:15","pubTimestamp":1763381709,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics (FDMT) said Monday it has named Kristian Humer as chief financial officer.Humer has more than two decades of experience including as managing director in Citi's (C) Healthcare Investment Banking unit, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0098860793.USD","LU0130102774.USD","FDMT","LU2360032135.SGD","LU0320765646.SGD","BK4207","LU0130517989.USD","XLV","IE00BSNM7G36.USD","LU0162691827.USD","LU1244550221.USD","LU1244550494.USD","LABU","BK4534","LU2236285917.USD","LU2417539215.USD","BK4566","XBI","LU0052756011.USD","LU1791807156.HKD","LU0980610538.SGD","LU1668664300.SGD","LU0128525689.USD","LU1366192091.USD","LU1162221912.USD","LU2125154935.USD","BK4585","LU0477156953.USD","BK4139","LU0170899867.USD","LU2462157665.USD","LU1201861249.SGD","BK4588","BK4504","LU1244550577.SGD","LU2456880835.USD","BK4559","LU0648001328.SGD","LU0310800965.SGD","LU1267930227.SGD","BK4581","LU2125154778.USD","LU0072461881.USD","LU0106831901.USD"],"gpt_icon":0},{"id":"2584420756","title":"4D Molecular names Kristian Humer as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584420756","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584420756?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:10","pubTimestamp":1763377833,"startTime":"0","endTime":"0","summary":"4D Molecular (FDMT) Therapeutics announced the appointment of Kristian Humer as CFO. Humer will lead the company’s financial strategy and operation...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/4d-molecular-names-kristian-humer-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/4d-molecular-names-kristian-humer-as-cfo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FDMT","BK4139"],"gpt_icon":0},{"id":"2584264235","title":"4Dmt Appoints Kristian Humer as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584264235","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584264235?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA2KQZDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FDMT","BK4139"],"gpt_icon":0},{"id":"2584440416","title":"Press Release: 4DMT Appoints Kristian Humer as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584440416","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584440416?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., Nov. 17, 2025  -- 4D Molecular Therapeutics , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives.4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF  with a single, safe, intravitreal injection, which substa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","FDMT","BK4588","BK4555","BK4585","03160","BK4099","BK4139","BK4604"],"gpt_icon":0},{"id":"2583681767","title":"4D Molecular Therapeutics Grants 45,400 RSUs to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681767?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154310,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc. has announced the grant of 45,400 Restricted Stock Units  to four new non-executive employees. The RSUs were awarded under the company's 2025 Employment Inducement Award Plan, which was approved by the board of directors in February 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL68qNxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","BK4588","LU0314104364.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ","LU2210149790.SGD","LU2095319765.USD","FDMT","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582970373","title":"Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582970373","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582970373?lang=en_us&edition=fundamental","pubTime":"2025-11-12 18:27","pubTimestamp":1762943272,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies 4D Molecular Therapeutics' stock price is sensitive to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fdmt/4d-molecular-therapeutics/news/institutional-investors-own-a-significant-stake-of-49-in-4d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fdmt/4d-molecular-therapeutics/news/institutional-investors-own-a-significant-stake-of-49-in-4d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FDMT","USAW.SI","SQQQ","QLD","MNQmain","BK4139",".IXIC","PSQ","USJW.SI","NVIW.SI","NQmain","TQQQ","TSYW.SI","QID"],"gpt_icon":1},{"id":"1198397095","title":"Stock Track | 4D Molecular Therapeutics Soars 5.21% Amid Positive Analyst Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1198397095","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198397095?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:26","pubTimestamp":1762874796,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics (FDMT) stock is soaring 5.21% in Tuesday's trading session, driven by a series of positive analyst updates. The biotechnology company, which focuses on the development of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["FDMT"],"gpt_icon":0},{"id":"2582361728","title":"4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361728","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582361728?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:25","pubTimestamp":1762867500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FDMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 08:25 ET (13:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.4dmoleculartherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1993},{"period":"1month","weight":-0.1963},{"period":"3month","weight":0.3152},{"period":"6month","weight":1.1017},{"period":"1year","weight":0.5017},{"period":"ytd","weight":0.5583}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.090662},{"month":2,"riseRate":0.2,"avgChangeRate":0.041082},{"month":3,"riseRate":0.6,"avgChangeRate":-0.023896},{"month":4,"riseRate":0.4,"avgChangeRate":-0.095608},{"month":5,"riseRate":0.6,"avgChangeRate":-0.116225},{"month":6,"riseRate":0.2,"avgChangeRate":-0.057799},{"month":7,"riseRate":0.8,"avgChangeRate":0.089973},{"month":8,"riseRate":0.4,"avgChangeRate":0.033931},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036288},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.6,"avgChangeRate":0.385036},{"month":12,"riseRate":0.2,"avgChangeRate":-0.015906}],"exchange":"NASDAQ","name":"4D Molecular Therapeutics","nameEN":"4D Molecular Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"4D Molecular Therapeutics(FDMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 4D Molecular Therapeutics(FDMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"4D Molecular Therapeutics,FDMT,4D Molecular Therapeutics股票,4D Molecular Therapeutics股票老虎,4D Molecular Therapeutics股票老虎国际,4D Molecular Therapeutics行情,4D Molecular Therapeutics股票行情,4D Molecular Therapeutics股价,4D Molecular Therapeutics股市,4D Molecular Therapeutics股票价格,4D Molecular Therapeutics股票交易,4D Molecular Therapeutics股票购买,4D Molecular Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"4D Molecular Therapeutics(FDMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 4D Molecular Therapeutics(FDMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction